
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Shares 2011-2025 | EPZM
Annual Shares Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 103 M | 101 M | 89.9 M | 71.9 M | 61.5 M | 57.1 M | 39.8 M | 33 M | 17 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 103 M | 17 M | 63.8 M |
Quarterly Shares Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 167 K | 144 K | 106 M | 103 M | 102 K | 102 K | 102 M | 102 M | 101 M | 99.6 M | 95.1 M | 91 M | 90.9 M | 82.4 M | 79 M | 69.5 M | 69.5 M | 69.4 M | 69.3 M | 59.9 M | 58.4 M | 58.2 M | 58 M | 58 M | 57.4 M | 55.1 M | 41.7 M | 41.5 M | 41.1 M | 35 M | 34.3 M | 33.7 M | 33.2 M | 31 M | 28.4 M | 28.4 M | 9.15 M | 1.79 M | 1.67 M | 1.65 M | 1.64 M | 1.62 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 106 M | 102 K | 50 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
48.4 M | $ 25.33 | -2.2 % | $ 1.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
166 M | $ 4.71 | 0.86 % | $ 782 M | ||
|
Aclaris Therapeutics
ACRS
|
77.3 M | $ 3.31 | -1.64 % | $ 256 M | ||
|
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
1.21 B | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
60.3 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
54.8 M | $ 210.45 | 0.14 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
5.45 M | $ 1.3 | -2.26 % | $ 7.09 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.4 | -0.71 % | $ 8.18 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Anika Therapeutics
ANIK
|
14.7 M | $ 9.53 | 0.42 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
5.39 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
1.37 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
30.8 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
6.28 M | $ 2.32 | 1.75 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
60.8 M | - | -6.81 % | $ 3.04 B | ||
|
AstraZeneca PLC
AZN
|
1.42 B | $ 89.4 | -0.99 % | $ 96.9 B | ||
|
Baudax Bio
BXRX
|
332 K | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
75.9 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
75.7 M | $ 570.03 | -1.89 % | $ 43.2 B | ||
|
Checkpoint Therapeutics
CKPT
|
39.7 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
8.33 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
116 M | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
146 M | $ 173.43 | 0.54 % | $ 25.3 B | ||
|
Cortexyme
CRTX
|
37.2 M | - | -1.05 % | $ 67.1 M | ||
|
BioVie
BIVI
|
1.48 M | $ 1.45 | -3.97 % | $ 2.14 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
85.1 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
64.7 M | $ 11.38 | -0.52 % | $ 736 M | ||
|
Benitec Biopharma
BNTC
|
41.2 M | $ 12.27 | -5.32 % | $ 505 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
2.17 M | - | -5.68 % | $ 8.28 M | ||
|
BioNTech SE
BNTX
|
244 M | $ 94.85 | -1.2 % | $ 27.2 B | ||
|
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.18 B | $ 0.28 | -2.0 % | $ 609 M | ||
|
Enochian Biosciences
ENOB
|
165 M | - | - | $ 40.5 M | ||
|
Catalyst Biosciences
CBIO
|
65.8 M | $ 14.5 | -5.29 % | $ 955 M | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | ||
|
Cerus Corporation
CERS
|
185 M | $ 2.13 | -0.7 % | $ 393 M | ||
|
Burford Capital Limited
BUR
|
219 M | $ 9.18 | 0.44 % | $ 1.5 B |